Although some therapeutic strategies, such as oral calcitonin, sclerostin inhibitors, or integrin antagonists, have been used for the treatment of postmenopausal osteoporosis [5], novel pharmacological interventions are urgently needed due to the limited efficiency and combined complications of current strategies for postmenopausal osteoporosis. The gene discussed is SOST; the disease is postmenopausal osteoporosis.